Arbutus Biopharma Corporation (NASDAQ:ABUS) Q1 2024 Earnings Call Transcript May 2, 2024
Arbutus Biopharma Corporation misses on earnings expectations. Reported EPS is $-0.10178 EPS, expectations were $-0.1. Arbutus Biopharma Corporation isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here).
Operator: Good day, and thank you for standing by. Welcome to the Arbutus Biopharma 2024 First Quarter Financial Results and Corporate Update...
